Amprius Technologies completed its at‑the‑market equity offering on January 12, 2026, raising $97.5 million in net proceeds after issuing 25.5 million shares of common stock. The program, authorized on October 2, 2023 for up to $100 million, was fully subscribed and the offering was terminated on the same day the proceeds were received.
The capital infusion expands the company’s liquidity base to $91.9 million in cash and cash equivalents as of December 31, 2025, up from $73.2 million at September 30, 2025 and $55.2 million at December 31, 2024. The steady growth in cash balances reflects disciplined working‑capital management and the company’s focus on scaling its silicon‑anode battery technology without heavy capital expenditures.
Prior to the offering, Amprius had 107.3 million shares outstanding; the issuance of 25.5 million new shares increased the total to 132.8 million, diluting existing shareholders by roughly 19 %. The company’s management views the dilution as a necessary trade‑off for the substantial capital that will accelerate product development and expand its customer base in aerospace and electric‑vehicle markets.
The proceeds will be deployed across research and development, capital‑light manufacturing partnerships, and strategic acquisitions. CEO Kang Sun emphasized that the funding will accelerate the company’s roadmap to commercial‑grade silicon‑anode batteries, enabling lighter, higher‑energy‑density cells for drones, electric aircraft, and light electric vehicles. The capital‑light model allows Amprius to scale production through contract manufacturers, reducing fixed‑asset risk while maintaining flexibility.
Management highlighted that the ATM offering demonstrates strong investor confidence in the company’s technology and growth prospects. “The market’s willingness to invest in our silicon‑anode platform confirms the value we are creating for customers in high‑performance sectors,” said Sun. The company plans to use the proceeds to secure additional supply‑chain agreements and to accelerate the deployment of its next‑generation cells.
Analysts continue to rate Amprius as a strong buy, citing the robust capital position, technology leadership, and expanding customer portfolio. The market reaction reflects confidence that the company can leverage the new capital to sustain its growth trajectory while maintaining a capital‑light manufacturing approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.